Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TransVascular CE-marks two PICVA (percutaneous in-situ coronary venous arterialisation) components:

This article was originally published in Clinica

Executive Summary

TransVascular has CE-marked for sale in Europe two components of its investigational system for performing a catheter-based coronary bypass procedure by diverting blood from a diseased artery in the heart to an adjacent vein. The two components of the company's PICVA (percutaneous in-situ coronary venous arterialisation) system are the coronary sinus guiding catheter and introducer and the subselective guiding catheter and introducer. The Menlo Park, California company said that "several" more components would have to be approved before the entire PICVA system would be available for sale.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel